MA urges medicines focus
September 10, 2010
MEDICINES Australia has today
urged the newly formed federal
government to focus on key
medicines and policy issues.
“The Australian medicines industry
welcomes the at least in-principle
expressions of support for the
Memorandum of Understanding
from the major political parties
before the election and we hope for
a speedy passage of the legislation
to implement savings,” said Medicines
Australia ceo, Dr Brendan Shaw.
“The MoU provides a predictable
policy environment for the Australian
medicines industry, a fiscally
sustainable PBS for the Government,
and lower prices for medicines and
improved access to new medicines
for Australian patients,” he added.
Shaw also threw his support behind
the proposed R&D tax credit reforms
and also called on the Gov to finalise
the Clinical Trials Action Group
report and to quickly process medicines
currently awaiting PBS listing which
were delayed by the election.
MEANWHILE Medicines
Australian has also welcomed three
new directors to its Board: Mr Dean
Phizacklea (Abbott), Mr Tim
McCormick (Biogen Idec) and Mr
Jim Cain (Bristol-Myers Squibb).
The appointments follow the
departures to overseas positions of
the incumbent directors Jeremy
Morgan from Eli Lilly and Jez
Moulding of sanofi-aventis, as well
as the the resignation of Dieter
Torheiden from Solvay.
The above article was sent to subscribers in Pharmacy Daily's issue from 10 Sep 10To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Sep 10
